Dual-hormone CLS delivering insulin and glucagon or insulin and the amylin analogue, pramlintide, aim to more closely imitate pancreatic glucose control physiology and may improve performance with regards to managing postprandial glucose excursions and exercise-induced hypoglycemia [88]. The gene discussed is GCG; the disease is Hypoglycemia.